

Pieter J Visser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1441385/publications.pdf>

Version: 2024-02-01

440
papers

34,114
citations

10979

71
h-index

4112

175
g-index

485
all docs

485
docs citations

485
times ranked

25504
citing authors

#	ARTICLE	IF	CITATIONS
1	Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. <i>Journal of Internal Medicine</i> , 2004, 256, 240-246.	2.7	4,039
2	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , The, 2007, 6, 734-746.	4.9	3,755
3	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , The, 2014, 13, 614-629.	4.9	2,657
4	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.4	1,863
5	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
6	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.	3.8	1,009
7	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. <i>Lancet Neurology</i> , The, 2009, 8, 619-627.	4.9	542
8	Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 714-718.	0.9	539
9	Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. <i>NeuroImage</i> , 2004, 23, 708-716.	2.1	522
10	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	3.8	501
11	Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 957-965.	4.9	471
12	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	4.9	464
13	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
14	Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. <i>Neurology</i> , 2004, 63, 94-100.	1.5	307
15	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 313-327.	1.2	307
16	Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. <i>Journal of Neurology</i> , 1999, 246, 477-485.	1.8	298
17	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. <i>Alzheimer's and Dementia</i> , 2019, 15, 888-898.	0.4	290
18	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	3.7	284

#	ARTICLE	IF	CITATIONS
19	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012, 6, 419-430.	0.6	280
20	Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 491-7.	0.9	259
21	The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.	0.4	249
22	Epigenetic regulation in the pathophysiology of Alzheimer's disease. <i>Progress in Neurobiology</i> , 2010, 90, 498-510.	2.8	237
23	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. <i>Alzheimer's and Dementia</i> , 2019, 15, 465-476.	0.4	232
24	Suspected non-Alzheimer disease pathophysiology "concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	4.9	230
25	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
26	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
27	Ten-year risk of dementia in subjects with mild cognitive impairment. <i>Neurology</i> , 2006, 67, 1201-1207.	1.5	191
28	Increased risk of mortality associated with social isolation in older men: only when feeling lonely? Results from the Amsterdam Study of the Elderly (AMSTEL). <i>Psychological Medicine</i> , 2012, 42, 843-853.	2.7	186
29	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 965-975.	4.9	175
30	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 439-442.	0.9	165
31	Cerebrospinal fluid A β 42 is the best predictor of clinical progression in patients with subjective complaints. <i>Alzheimer's and Dementia</i> , 2013, 9, 481-487.	0.4	164
32	Predictive Accuracy of MCI Subtypes for Alzheimer's Disease and Vascular Dementia in Subjects with Mild Cognitive Impairment: A 2-Year Follow-Up Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 113-119.	0.7	162
33	Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , 2012, 78, 468-476.	1.5	154
34	Retinal thickness in Alzheimer's disease: A systematic review and meta-analysis. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 162-170.	1.2	152
35	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144
36	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 353-366.	1.4	140

#	ARTICLE	IF	CITATIONS
37	Predictive value of APOE- $\epsilon 4$ allele for progression from MCI to AD-type dementia: a meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1149-1156.	0.9	136
38	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.	0.4	134
39	Association of Cerebral Amyloid- $\beta 2$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
40	Prevalence of amyloid- $\beta 2$ pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	2.8	132
41	Thalamic volume predicts performance on tests of cognitive speed and decreases in healthy aging. <i>Cognitive Brain Research</i> , 2001, 11, 377-385.	3.3	131
42	Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 881-891.	1.2	130
43	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <i>Neurology</i> , 2012, 79, 1809-1816.	1.5	129
44	Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0136181.	1.1	129
45	Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer's disease. <i>Brain Structure and Function</i> , 2011, 215, 265-271.	1.2	126
46	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- $\beta 42$ Analysis Results. <i>Clinical Chemistry</i> , 2018, 64, 576-585.	1.5	126
47	New MRI Markers for Alzheimer's Disease: A Meta-Analysis of Diffusion Tensor Imaging and a Comparison with Medial Temporal Lobe Measurements. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 405-429.	1.2	125
48	The relation between global and limbic brain volumes on MRI and cognitive performance in healthy individuals across the age range. <i>Neurobiology of Aging</i> , 2000, 21, 569-576.	1.5	123
49	Preclinical AD predicts decline in memory and executive functions in subjective complaints. <i>Neurology</i> , 2013, 81, 1409-1416.	1.5	122
50	Hippocampal volume change measurement: Quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. <i>NeuroImage</i> , 2014, 92, 169-181.	2.1	117
51	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 274-284.	0.4	113
52	Prediction of Alzheimer disease in subjects with amnesic and nonamnesic MCI. <i>Neurology</i> , 2013, 80, 1124-1132.	1.5	110
53	Distinction Between Preclinical Alzheimer's Disease and Depression. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 479-484.	1.3	108
54	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017, 13, 285-295.	0.4	108

#	ARTICLE	IF	CITATIONS
55	Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1348-1354.	0.9	107
56	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. <i>Brain</i> , 2018, 141, 3443-3456.	3.7	102
57	Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. <i>Neurobiology of Aging</i> , 2010, 31, 1787-1798.	1.5	97
58	ATN classification and clinical progression in subjective cognitive decline. <i>Neurology</i> , 2020, 95, e46-e58.	1.5	97
59	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
60	Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 537-547.	1.2	95
61	Optical coherence tomography angiography in preclinical Alzheimer's disease. <i>British Journal of Ophthalmology</i> , 2020, 104, 157-161.	2.1	95
62	Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. <i>Psychological Medicine</i> , 2013, 43, 911-920.	2.7	93
63	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654.	0.4	90
64	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	3.7	89
65	Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer's Disease. <i>Neuroepidemiology</i> , 2008, 30, 254-265.	1.1	86
66	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2013, 34, 2003-2013.	1.5	86
67	Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. <i>NeuroImage</i> , 2016, 124, 442-454.	2.1	85
68	Age dependency of risk factors for cognitive decline. <i>BMC Geriatrics</i> , 2018, 18, 187.	1.1	85
69	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	4.9	85
70	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.4	82
71	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. <i>Neurobiology of Aging</i> , 2016, 44, 1-8.	1.5	80
72	36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 29-40.	0.4	77

#	ARTICLE	IF	CITATIONS
73	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> , 2012, 33, 2272-2281.	1.5	75
74	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 319-327.	1.2	73
75	Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. <i>PLoS ONE</i> , 2014, 9, e100784.	1.1	72
76	Brain correlates of memory dysfunction in alcoholic Korsakoff's syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 67, 774-778.	0.9	71
77	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	1.8	70
78	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 27.	3.0	66
79	Predictive Value of Mild Cognitive Impairment for Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 173-181.	0.7	65
80	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a European ADNI study. <i>Journal of Internal Medicine</i> , 2016, 279, 576-591.	2.7	64
81	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 100.	3.0	64
82	Heritability estimates for 361 blood metabolites across 40 genome-wide association studies. <i>Nature Communications</i> , 2020, 11, 39.	5.8	64
83	Characteristics of help-seeking behaviour in subjects with subjective memory complaints at a memory clinic: a case-control study. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 190-196.	1.3	63
84	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.	3.0	62
85	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.4	62
86	Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study. <i>Psychological Medicine</i> , 2010, 40, 1193-1201.	2.7	61
87	Genetic Loci Associated with Alzheimer's Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort. <i>PLoS ONE</i> , 2013, 8, e59676.	1.1	61
88	Unbiased estimates of cerebrospinal fluid β -amyloid 1-42 cutoffs in a large memory clinic population. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 8.	3.0	60
89	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 167-182.e1.	1.5	60
90	Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2-Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia Alzheimer's Disease Study. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 2273-2281.	1.3	59

#	ARTICLE	IF	CITATIONS
91	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnesic mild cognitive impairment (MCI). <i>Neurobiology of Aging</i> , 2017, 53, 1-10.	1.5	59
92	The Association between APOE Genotype and Memory Dysfunction in Subjects with Mild Cognitive Impairment Is Related to Age and Alzheimer Pathology. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 101-108.	0.7	58
93	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
94	Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 26-35.	1.2	58
95	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.4	56
96	Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 511-522.	0.4	55
97	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.5	55
98	Brain SPECT in subtypes of mild cognitive impairment. <i>Journal of Neurology</i> , 2008, 255, 1344-1353.	1.8	54
99	Use of amyloid-PET to determine cutpoints for CSF markers. <i>Neurology</i> , 2016, 86, 50-58.	1.5	54
100	Amyloid- β 2 Oligomers Relate to Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 35-43.	1.2	52
101	Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. <i>Journal of Neurology</i> , 2002, 249, 312-319.	1.8	51
102	The ICTUS Study: A Prospective Longitudinal Observational Study of 1,380 AD Patients in Europe. <i>Neuroepidemiology</i> , 2007, 29, 29-38.	1.1	51
103	Gray matter network disruptions and amyloid beta in cognitively normal adults. <i>Neurobiology of Aging</i> , 2016, 37, 154-160.	1.5	51
104	Mild cognitive impairment as predictor for Alzheimer's disease in clinical practice: effect of age and diagnostic criteria. <i>Psychological Medicine</i> , 2008, 38, 113-122.	2.7	50
105	The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. <i>Neurobiology of Aging</i> , 2012, 33, 201.e1-201.e8.	1.5	48
106	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 75.	3.0	48
107	Biomarker profiles and their relation to clinical variables in mild cognitive impairment. <i>Neurocase</i> , 2005, 11, 8-13.	0.2	47
108	Symptoms of Preclinical Dementia in General Practice up to Five Years before Dementia Diagnosis. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 300-306.	0.7	47

#	ARTICLE	IF	CITATIONS
109	Comparison of International Working Group criteria and National Institute on Aging's Alzheimer's Association criteria for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, 560-563.	0.4	47
110	Assessing Amyloid Pathology in Cognitively Normal Subjects Using ¹⁸ F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. <i>Journal of Nuclear Medicine</i> , 2019, 60, 541-547.	2.8	47
111	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	3.0	46
112	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.4	46
113	Course of objective memory impairment in non-demented subjects attending a memory clinic and predictors of outcome. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 363-372.	1.3	45
114	Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 1149-1159.	0.4	45
115	The Dementias Platform UK (DPUK) Data Portal. <i>European Journal of Epidemiology</i> , 2020, 35, 601-611.	2.5	45
116	Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. <i>Alzheimer's and Dementia</i> , 2018, 14, 130-139.	0.4	44
117	Time from diagnosis to institutionalization and death in people with dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 662-671.	0.4	44
118	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.	0.4	44
119	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 101.	3.0	43
120	SPECT Predictors of Cognitive Decline and Alzheimer's Disease in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 761-772.	1.2	42
121	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.	2.4	42
122	Single-Domain Amnesic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 1-19.	0.7	41
123	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 86-98.	2.7	40
124	Spatial-Temporal Patterns of β^2 -Amyloid Accumulation. <i>Neurology</i> , 2022, 98, .	1.5	40
125	White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1069-1074.	0.9	39
126	The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. <i>Psychological Medicine</i> , 2015, 45, 1509-1519.	2.7	39

#	ARTICLE	IF	CITATIONS
127	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. <i>Human Brain Mapping</i> , 2016, 37, 2114-2132.	1.9	38
128	Functional and effective whole brain connectivity using magnetoencephalography to identify monozygotic twin pairs. <i>Scientific Reports</i> , 2017, 7, 9685.	1.6	38
129	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. <i>NeuroImage</i> , 2020, 218, 116932.	2.1	38
130	Impact of APOE-É4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. <i>Neurobiology of Aging</i> , 2016, 38, 14-20.	1.5	37
131	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. <i>Neurology</i> , 2021, 96, e2673-e2684.	1.5	37
132	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	1.1	36
133	Retinal layer thickness in preclinical Alzheimer's disease. <i>Acta Ophthalmologica</i> , 2019, 97, 798-804.	0.6	36
134	Differential insular cortex sub-regional atrophy in neurodegenerative diseases: a systematic review and meta-analysis. <i>Brain Imaging and Behavior</i> , 2020, 14, 2799-2816.	1.1	36
135	Normal Cognitive Performance in Patients With Chronic Alcoholism in Contrast to Patients With Korsakoff's Syndrome. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2000, 12, 44-50.	0.9	34
136	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite <sc>E</sc>uropean 3T study on healthy elderly. <i>Human Brain Mapping</i> , 2015, 36, 3516-3527.	1.9	34
137	Two-Year Longitudinal Monitoring of Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 15-35.	1.2	34
138	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1025-1034.	1.2	33
139	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , 2017, 13, 903-912.	0.4	32
140	Age and the association of dementia-related pathology with trajectories of cognitive decline. <i>Neurobiology of Aging</i> , 2018, 61, 138-145.	1.5	32
141	Diagnosis of Preclinical Alzheimer's Disease in a Clinical Setting. <i>International Psychogeriatrics</i> , 2001, 13, 411-423.	0.6	31
142	Consensus statement on dementia education and training in Europe. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 131-135.	1.5	31
143	Generalizability of the Disease State Index Prediction Model for Identifying Patients Progressing from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 79-92.	1.2	31
144	Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1477-1487.	1.2	31

#	ARTICLE	IF	CITATIONS
145	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.	4.4	30
146	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 67.	1.7	29
147	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, 750-758.	0.4	29
148	Medial Temporal Lobe Atrophy and APOE Genotype Do Not Predict Cognitive Improvement upon Treatment with Rivastigmine in Alzheimer's Disease Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 126-133.	0.7	28
149	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 409.	1.7	28
150	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 74.	3.0	28
151	White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1827-1834.	1.3	28
152	APOE ϵ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65.	3.0	28
153	Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 89.	3.0	28
154	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e13-1605.e20.	1.5	27
155	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	1.5	27
156	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1119-1128.	1.2	27
157	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101786.	1.4	27
158	A framework for assessing neuropsychiatric phenotypes by using smartphone-based location data. <i>Translational Psychiatry</i> , 2020, 10, 211.	2.4	27
159	Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration. <i>Scientific Reports</i> , 2021, 11, 22675.	1.6	27
160	Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?. , 2006, 2, 220-233.		25
161	Relationship between genetic risk factors and markers for Alzheimer's disease pathology. <i>Biomarkers in Medicine</i> , 2012, 6, 477-495.	0.6	25
162	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 73.	3.0	25

#	ARTICLE	IF	CITATIONS
163	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. <i>BMC Geriatrics</i> , 2018, 18, 289.	1.1	25
164	Retinal thickness as a potential biomarker in patients with amyloid- β -proven early- and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 463-471.	1.2	25
165	Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. <i>BMC Neurology</i> , 2012, 12, 72.	0.8	24
166	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1387-1395.	1.2	24
167	Challenges for Optimizing Real-World Evidence in Alzheimer's Disease: The ROADMAP Project. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 495-501.	1.2	24
168	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. <i>Magnetic Resonance Imaging</i> , 2021, 76, 108-115.	1.0	24
169	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. <i>Alzheimer's and Dementia</i> , 2022, 18, 29-42.	0.4	24
170	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. <i>Epigenomics</i> , 2015, 7, 533-537.	1.0	23
171	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1037-1047.	1.7	23
172	Plasma A β 242 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnesic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 37-48.	1.2	23
173	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.4	23
174	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. <i>Current Alzheimer Research</i> , 2015, 12, 69-79.	0.7	22
175	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
176	Progression to dementia in memory clinic patients without dementia. <i>Neurology</i> , 2013, 81, 1342-1349.	1.5	21
177	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. <i>Journal of Psychiatric Research</i> , 2018, 104, 183-191.	1.5	21
178	The Diagnostic and Prognostic Value of Neuropsychological Assessment in Memory Clinic Patients. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 679-689.	1.2	20
179	Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2016, 252, 26-35.	0.9	20
180	Low normal cerebrospinal fluid A β 242 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , 2017, 81, 749-753.	2.8	20

#	ARTICLE	IF	CITATIONS
181	White matter hyperintensities and vascular risk factors in monozygotic twins. <i>Neurobiology of Aging</i> , 2018, 66, 40-48.	1.5	20
182	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 837-842.	0.4	20
183	The MOPEAD project: Advancing patient engagement for the detection of "hidden" undiagnosed cases of Alzheimer's disease in the community. , 2019, 15, 828-839.		20
184	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 94.	3.0	20
185	The European medical information framework: A novel ecosystem for sharing healthcare data across Europe. <i>Learning Health Systems</i> , 2020, 4, e10214.	1.1	20
186	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. <i>Annals of Neurology</i> , 2021, 89, 987-1000.	2.8	20
187	MCI is not a clinically useful concept. <i>International Psychogeriatrics</i> , 2006, 18, 402-9; discussion 409-14.	0.6	20
188	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	1.7	20
189	Can novel therapeutics halt the amyloid cascade?. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 5.	3.0	19
190	Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment. <i>Biomarkers in Medicine</i> , 2012, 6, 365-368.	0.6	19
191	The association of vascular disorders with incident dementia in different age groups. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 47.	3.0	19
192	Plasma amyloid- β^2 oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 133.	3.0	19
193	Regional Differences in Effects of ϵ -APOE ϵ 4 on Cognitive Impairment in Non-Demented Subjects. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 135-142.	0.7	18
194	Predicting and Tracking Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 3-14.	1.2	18
195	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 2.	3.0	18
196	The Effect of Psychological Distress and Personality Traits on Cognitive Performances and the Risk of Dementia in Patients with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 805-812.	1.2	17
197	The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 513-523.	1.8	17
198	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. <i>Alzheimer's and Dementia</i> , 2014, 10, 456-467.	0.4	16

#	ARTICLE	IF	CITATIONS
199	Genetic Risk as a Marker of Amyloid- β^2 and Tau Burden in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1417-1427.	1.2	16
200	Amyloid- β^2 , Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 193.	1.7	16
201	White matter microstructure disruption in early stage amyloid pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12124.	1.2	16
202	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 712545.	1.7	16
203	Course of minimal dementia and predictors of outcome. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 835-841.	1.3	15
204	Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform. <i>Alzheimer's and Dementia</i> , 2015, 11, 1121-1122.	0.4	15
205	Brain Amyloid Pathology and Cognitive Function. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2285.	3.8	15
206	Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions. , 2018, 59, 5025.		15
207	The Effect of the APOE- ϵ^4 Allele and ACE-I/D Polymorphism on Cognition during a Two-Year Follow-Up in First-Ever Stroke Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 534-542.	0.7	14
208	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. <i>Neurobiology of Aging</i> , 2019, 77, 58-65.	1.5	14
209	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 1-9.	1.2	14
210	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 1499-1511.	2.4	14
211	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 138.	3.0	14
212	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. <i>Brain Communications</i> , 2021, 3, fcab201.	1.5	14
213	Amyloid imaging in the prediction of Alzheimer-type dementia in subjects with amnesic MCI. <i>Neurology</i> , 2009, 73, 744-745.	1.5	13
214	Real-world evidence in Alzheimer's disease: The ROADMAP Data Cube. <i>Alzheimer's and Dementia</i> , 2020, 16, 461-471.	0.4	13
215	Longitudinal retinal layer changes in preclinical Alzheimer's disease. <i>Acta Ophthalmologica</i> , 2021, 99, 538-544.	0.6	13
216	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	1.2	13

#	ARTICLE	IF	CITATIONS
217	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1061-1070.	1.2	13
218	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.4	13
219	Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 146-151.	0.6	12
220	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 8.	3.0	12
221	Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case-control study using European electronic health records. <i>BMJ Open</i> , 2020, 10, e038753.	0.8	12
222	Insights into the changes in the proteome of Alzheimer disease elucidated by a meta-analysis. <i>Scientific Data</i> , 2021, 8, 312.	2.4	12
223	Genetically identical twins show comparable tau PET load and spatial distribution. <i>Brain</i> , 2022, 145, 3571-3581.	3.7	12
224	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 201-210.	1.2	11
225	CSF cutoffs for MCI due to AD depend on APOE ϵ 4 carrier status. <i>Neurobiology of Aging</i> , 2020, 89, 55-62.	1.5	11
226	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. <i>Brain Communications</i> , 2020, 2, fcaa102.	1.5	11
227	The Predictive Value of Memory Strategies for Alzheimer's Disease in Subjects with Mild Cognitive Impairment. <i>Archives of Clinical Neuropsychology</i> , 2010, 25, 71-77.	0.3	10
228	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	1.2	10
229	Cognitive functioning of individuals aged 90 years and older without dementia: A systematic review. <i>Ageing Research Reviews</i> , 2017, 36, 42-49.	5.0	10
230	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. <i>Neurology</i> , 2019, 92, e2699-e2705.	1.5	10
231	General practitioners' attitude toward early and pre-dementia diagnosis of AD in five European countries: A MOPEAD project survey. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12130.	1.2	10
232	ALZHEIMER'S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIET TRIAL IN PRODROMAL ALZHEIMER'S DISEASE. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2019, 6, 1-5.	1.5	10
233	Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer's disease biomarkers. <i>Clinical Proteomics</i> , 2022, 19, 13.	1.1	10
234	Amyloid β , cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 348-358.	1.7	9

#	ARTICLE	IF	CITATIONS
235	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	1.7	9
236	A methodology for cohort harmonisation in multicentre clinical research. <i>Informatics in Medicine Unlocked</i> , 2021, 27, 100760.	1.9	9
237	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. <i>Molecular Psychiatry</i> , 2022, 27, 1990-1999.	4.1	9
238	Regional associations of white matter hyperintensities and early cortical amyloid pathology. <i>Brain Communications</i> , 2022, 4, .	1.5	9
239	Characteristics of preclinical Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 88-89.	1.3	8
240	CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer's Disease Consortium (EADC). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 124-125.	0.9	8
241	Biomarkers for Alzheimer's disease: a controversial topic. <i>Lancet Neurology</i> , The, 2015, 14, 781-783.	4.9	8
242	Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 875-885.	1.2	8
243	Preclinical Alzheimer's Disease: Implications for Refinement of the Concept. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S213-S227.	1.2	8
244	Biomarker Matrix to Track Short Term Disease Progression in Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 49-58.	1.2	8
245	Ocular biomarkers for cognitive impairment in nonagenarians; a prospective cross-sectional study. <i>BMC Geriatrics</i> , 2020, 20, 155.	1.1	8
246	Duration of Care Trajectories in Persons With Dementia Differs According to Demographic and Clinical Characteristics. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1102-1107.e6.	1.2	8
247	Identification of undiagnosed dementia cases using a web-based pre-screening tool: The MOPEAD project. <i>Alzheimer's and Dementia</i> , 2021, 17, 1307-1316.	0.4	8
248	Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 264-277.	1.3	8
249	Role of cognitive testing in disease modifying AD trials. <i>Journal of Nutrition, Health and Aging</i> , 2006, 10, 131-2; discussion 132-3.	1.5	8
250	Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's A β 2 amyloidosis. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	2.4	8
251	The Association Between APOE ϵ 4 and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 241-246.	1.2	7
252	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1609-1617.	1.7	7

#	ARTICLE	IF	CITATIONS
253	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	1.2	7
254	Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2020, 93, 144.e1-144.e15.	1.5	7
255	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12216.	1.2	7
256	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicine</i> , 2021, 9, 1610.	1.4	7
257	Phenomenology of Depression in Dementia. <i>International Psychogeriatrics</i> , 2000, 12, 129-134.	0.6	6
258	Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1177.	3.8	6
259	Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 256-264.	1.2	6
260	Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 64.	3.0	6
261	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-C4C2 repeats that predisposes to pathological repeat expansions. <i>Translational Psychiatry</i> , 2021, 11, 451.	2.4	6
262	MILD COGNITIVE IMPAIRMENT SUBTYPES AND VASCULAR DEMENTIA. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1966-1967.	1.3	5
263	Genetic overlap between Alzheimer's disease and blood lipid levels. <i>Neurobiology of Aging</i> , 2021, 108, 189-195.	1.5	5
264	Magnetoencephalography Brain Signatures Relate to Cognition and Cognitive Reserve in the Oldest-Old: The EMIF-AD 90 + Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 746373.	1.7	5
265	P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	5
266	Mild Cognitive Impairment. , 0, , 1095-1101.		4
267	Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 344-345.	1.5	4
268	<i>APOE</i> ϵ 4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community setting. <i>The Cochrane Library</i> , 0, , .	1.5	4
269	<i>APOE</i> ϵ 4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care setting. <i>The Cochrane Library</i> , 0, , .	1.5	4
270	<i>APOE</i> ϵ 4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care setting. <i>The Cochrane Library</i> , 0, , .	1.5	4

#	ARTICLE	IF	CITATIONS
271	[P4â€“157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€“OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1319.	0.4	4
272	[O2â€“12â€“03]: DURATION OF ALZHEIMER'S DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTIâ€“STATE MODEL ANALYSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P585.	0.4	4
273	Capturing the Alzheimer's disease pathological cascade. <i>Lancet Neurology</i> , The, 2018, 17, 199-200.	4.9	4
274	A Cost-Consequence Analysis of Different Screening Procedures in Alzheimerâ€™s Disease: Results from the MOPEAD Project. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1149-1159.	1.2	4
275	Effects of age, amyloid, sex, and <i>APOE</i> ϵ 4 on the CSF proteome in normal cognition. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12286.	1.2	4
276	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€“Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2023, 19, 807-820.	0.4	4
277	Magnesium therapy in acute myocardial infarction. <i>Netherlands Journal of Medicine</i> , 1995, 46, 156-165.	0.6	3
278	P4â€“224: Alzheimerâ€™s Disease Patients With Osas History Have Higher CSF Tau Levels. <i>Alzheimer's and Dementia</i> , 2016, 12, P1115.	0.4	3
279	Microvascular changes of the retina in ankylosing spondylitis, and the association with cardiovascular disease â€“ the eye for a heart study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1535-1541.	1.6	3
280	Complementary preâ€“screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project. <i>Alzheimer's and Dementia</i> , 2021, , .	0.4	3
281	MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study. <i>Current Alzheimer Research</i> , 2016, 13, 1407-1413.	0.7	3
282	CSF proteomic signature predicts progression to Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12240.	1.8	3
283	Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	3
284	P2-274: Risk score profiles for prediction of dementia in the general elderly population. , 2015, 11, P596-P596.		2
285	P2-188: Characterization of cognitive function with the cantab in individuals with amnesic mild cognitive impairment in relation to hippocampal volume, amyloid, and tau status: Preliminary baseline results from the PharmaCog/european-ADNI study. , 2015, 11, P564-P564.		2
286	O3-05-03: Modifiable Risk Factors for Prevention of Dementia in Midlife and Late Life: The Libra Index. , 2016, 12, P295-P296.		2
287	ICâ€“Pâ€“120: Association Between Brain MRI Diffusion Alterations and CSF Biomarkers in Amnesic MCI. <i>Alzheimer's and Dementia</i> , 2016, 12, P89.	0.4	2
288	DTâ€“01â€“04: Effects of Fortasyn Connect (Souvenaid) on Longitudinal Brain Atrophy Measures in Prodromal Alzheimerâ€™s Disease: Results of the Doubleâ€“Blind Randomised Controlled Lipid diet Trial. <i>Alzheimer's and Dementia</i> , 2016, 12, P1135.	0.4	2

#	ARTICLE	IF	CITATIONS
289	ICâ€Pâ€039: Impairment of Restingâ€State Functional Connectivity in The Defaultâ€Mode Network Closely Tracks CSF Biomarkers In MCI. Alzheimer's and Dementia, 2016, 12, P34.	0.4	2
290	Chasing the start of sporadic Alzheimerâ€™s disease running in families. Brain, 2018, 141, 1589-1591.	3.7	2
291	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. Alzheimer's and Dementia, 2020, 16, e037184.	0.4	2
292	Proteomic correlates of cortical thickness in cognitively normal individuals with normal and abnormal cerebrospinal fluid beta-amyloid1-42. Neurobiology of Aging, 2021, 107, 42-52.	1.5	2
293	Assessment of Social Behavior Using a Passive Monitoring App in Cognitively Normal and Cognitively Impaired Older Adults: Observational Study. JMIR Aging, 2022, 5, e33856.	1.4	2
294	An app to measure functional decline in managing finances in Alzheimerâ€™s disease: Preliminary results of the RADARâ€AD study. Alzheimer's and Dementia, 2021, 17, .	0.4	2
295	Dataâ€driven evidence for three distinct patterns of amyloidâ€™ ² accumulation. Alzheimer's and Dementia, 2021, 17, .	0.4	2
296	Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology, 2007, 68, 1238-1239.	1.5	1
297	Fluid biomarkers for Alzheimerâ€™s disease: standardization and recent developments. Biomarkers in Medicine, 2012, 6, 363-364.	0.6	1
298	O3-08-01: The prevalence of amyloid pathology in healthy individuals and individuals with mild cognitive impairment: A meta-analysis of amyloid-PET studies. , 2013, 9, P533-P533.		1
299	FTS-01-01: A european medical information framework for Alzheimer's disease (EMIF-AD). , 2015, 11, P120-P121.		1
300	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
301	P3â€15: Differential Effects of Apoe and CSF Amyloid on Memory Impairment in Individuals with Amnestic MCI Using the Cantab Cognitive Battery: Results from the Europeanâ€Adni Study. Alzheimer's and Dementia, 2016, 12, P964.	0.4	1
302	P4â€153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Nonâ€AD in Memory Clinic and Communityâ€Based Cohorts. Alzheimer's and Dementia, 2016, 12, P1073.	0.4	1
303	[P2â€12]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER'S DISEASE (EMIFâ€AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.4	1
304	P4â€158: THE ASSOCIATION OF VASCULAR DISORDERS WITH INCIDENT DEMENTIA AND MORTALITY IN DIFFERENT AGE GROUPS IN A PRIMARY CARE DATABASE. Alzheimer's and Dementia, 2018, 14, P1499.	0.4	1
305	ICâ€Pâ€182: EVENTâ€BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL Î²â€AMYLOID DEPOSITION IN THE BRAIN. Alzheimer's and Dementia, 2018, 14, P152.	0.4	1
306	ICâ€Pâ€126: VOLUMETRIC ACCURACY OF A FULLY AUTOMATIC TOOL FOR WHITE MATTER HYPERINTENSITIES (WMHS) SEGMENTATION. Alzheimer's and Dementia, 2018, 14, P105.	0.4	1

#	ARTICLE	IF	CITATIONS
307	P2-445: EVENT-BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL β -AMYLOID DEPOSITION IN THE BRAIN. Alzheimer's and Dementia, 2018, 14, P887.	0.4	1
308	P1-247: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AS A DIFFERENTIAL DIAGNOSIS BIOMARKER IN NEUROLOGICAL DISEASES: A SYSTEMATIC REVIEW AND METAANALYSIS. Alzheimer's and Dementia, 2018, 14, P373.	0.4	1
309	Predictors of preclinical Alzheimer's disease in persons with subjective cognitive decline. Alzheimer's and Dementia, 2020, 16, e042658.	0.4	1
310	The IMI-EU H2020 project MOPEAD: Outcome of different screening methods to identify MCI/early AD. Alzheimer's and Dementia, 2020, 16, e044524.	0.4	1
311	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. Alzheimer's and Dementia, 2020, 16, e044787.	0.4	1
312	Pre-screening models for patient engagement: The MOPEAD project. Alzheimer's and Dementia, 2020, 16, e044796.	0.4	1
313	Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD. Alzheimer's and Dementia, 2020, 16, e045230.	0.4	1
314	Social behavior assessment in cognitively impaired older adults using a passive and remote smartphone application. Alzheimer's and Dementia, 2021, 17, e051698.	0.4	1
315	Updated prevalence estimates of amyloid positivity from cognitively normal to clinical Alzheimer's disease dementia: The Amyloid Biomarker Study. Alzheimer's and Dementia, 2021, 17, .	0.4	1
316	Augmented reality to detect subtle alterations in the early stages of Alzheimer's disease: Preliminary results of the RADAR-AD study. Alzheimer's and Dementia, 2021, 17, .	0.4	1
317	Gait characteristics in preclinical Alzheimer's disease: Preliminary results of the RADAR-AD study. Alzheimer's and Dementia, 2021, 17, .	0.4	1
318	S1-02-02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia. , 2013, 9, P122-P122.		0
319	IC-P-224: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS. , 2014, 10, P120-P121.		0
320	O2-05-03: USE OF CSF AMYLOID FOR DETECTING CORTICAL AMYLOID DEPOSITION: A MULTICENTER STUDY. , 2014, 10, P173-P173.		0
321	P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly. , 2015, 11, P689-P689.		0
322	P4-040: Use of recent research criteria for inclusion and use of biomarkers as endpoint in preclinical and prodromal Alzheimer's disease (AD) trials: An Alzheimer's disease neuroimaging initiative (ADNI) study. , 2015, 11, P780-P781.		0
323	O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF). , 2015, 11, P130-P130.		0
324	O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test. , 2015, 11, P272-P272.		0

#	ARTICLE	IF	CITATIONS
325	IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly. , 2015, 11, P11-P11.		0
326	O1-03-06: Creating normative values for cognitive tests in amyloid positive and amyloid negative cognitively normal subjects. , 2015, 11, P131-P132.		0
327	IC-P-108: Impact of ApoE-ε4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P73-P73.		0
328	P1-011: Prevalence of amyloid and neurodegeneration markers and effects on cognitive functioning in non-demented subjects. , 2015, 11, P340-P341.		0
329	O2-09-01: Impact of ApoE-ε4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P194-P194.		0
330	F3-02-03: Prevalence of snap in subjects with mild cognitive impairment and dementia. , 2015, 11, P213-P214.		0
331	O3-11-02: Prevalence and diagnostic procedures in early-onset dementia in tertiary referral center patients in denmark, sweden, and the netherlands. , 2015, 11, P244-P245.		0
332	F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors. , 2015, 11, P260-P261.		0
333	P3-031: EPAD Register: A Novel Tool for Pre-Screening Participants in the IMI European Prevention of Alzheimer's Dementia Project (EPAD). , 2016, 12, P828-P829.		0
334	P4-122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.4	0
335	IC-P-017: Concordance of [18F]Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P23.	0.4	0
336	IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P7-P8.		0
337	P1-264: Structural and Diffusion Tensor Imaging in MCI Subjects With Intermediate Risk of Alzheimer's Disease Based on CSF Profile. Alzheimer's and Dementia, 2016, 12, P514.	0.4	0
338	P1-366: Subjective Versus Objective Cognitive Decline in Memory Clinic Visitors. , 2016, 12, P571-P571.		0
339	P2-165: Resilience to Clinical Dementia at Old Age: The European Medical Information Framework (EMIF) 90+ Study. , 2016, 12, P678-P678.		0
340	P2-237: Concordance of [18F] Flutemetamol Amyloid Deposition in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P714-P715.		0
341	IC-P-122: Structural and Diffusion Tensor Imaging in MCI Subjects With Intermediate Risk of Alzheimer's Disease Based on CSF Profile. Alzheimer's and Dementia, 2016, 12, P90.	0.4	0
342	IC-P-147: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.	0.4	0

#	ARTICLE	IF	CITATIONS
343	ICâ€Pâ€148: Association Between Volumes Alterations and CSF Biomarkers in Amnestic MCI. Alzheimer's and Dementia, 2016, 12, P110.	0.4	0
344	P3â€232: Association Between Brain MRI Diffusion Alterations and CSF Biomarkers in Amnestic MCI. Alzheimer's and Dementia, 2016, 12, P914.	0.4	0
345	P3â€269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P935.	0.4	0
346	P4â€112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Nonâ€Demented Elderly. Alzheimer's and Dementia, 2016, 12, P1055.	0.4	0
347	P4â€146: Largeâ€Vessel Disease and [18F]Flutemetamolâ€Amyloid Deposition in Cognitively Healthy Elderly Twins. Alzheimer's and Dementia, 2016, 12, P1069.	0.4	0
348	P4-165: Association Between Volume Alterations and CSF Biomarkers in Amnestic MCI. , 2016, 12, P1080-P1080.		0
349	O1-11-03: Prevalence of Amyloid-b Pathology in Primary Progressive Aphasia Variants: A Multicenter Study. , 2016, 12, P202-P203.		0
350	O2â€04â€01: Cognitive Composite Measures in Amnestic MCI by Different AMYLOID/TAU Pathology. Alzheimer's and Dementia, 2016, 12, P229.	0.4	0
351	O2â€05â€02: Dementia Prevalence and Incidence in a Combination of European Electronic Health Records Databases: the EMIFâ€ad EHR Resource. Alzheimer's and Dementia, 2016, 12, P232.	0.4	0
352	O3â€05â€02: Relation Between Lifestyle Factors and Alzheimer's Disease Biomarkers in Subjects with SCI or MCI. Alzheimer's and Dementia, 2016, 12, P294.	0.4	0
353	O3-09-02: Cognitive Consequences of Cerebral Amyloid Pathology in Persons without Dementia. , 2016, 12, P307-P308.		0
354	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P335.	0.4	0
355	P1â€238: When Less is More: Detecting Functional Decline Using a Short Version of the Amsterdam Iadl Questionnaire. Alzheimer's and Dementia, 2016, 12, P498.	0.4	0
356	P4â€350: Biomarkers of Short Term Disease Progression in Mild Cognitive Impairment Patients with ad Pathology. Alzheimer's and Dementia, 2016, 12, P1171.	0.4	0
357	O4â€09â€05: Risk Factors for Cognitive Decline are Age Dependent. Alzheimer's and Dementia, 2016, 12, P356.	0.4	0
358	[P2â€399]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P783.	0.4	0
359	[P3â€062]: ACROSSâ€SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTIâ€SITE 3T STUDY. Alzheimer's and Dementia, 2017, 13, P954.	0.4	0
360	[P3â€214]: ADFLAG^{â€}, A DIAGNOSTIC BLOOD TEST FOR PREâ€DEMENTIA STAGES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1019.	0.4	0

#	ARTICLE	IF	CITATIONS
361	[P4â€“226]: BEST COMBINATORIAL LOWâ€“COST MARKERS TO PREDICT MCI CONVERSION: AN EMIFâ€“AD FEDERATION STUDY. Alzheimer's and Dementia, 2017, 13, P1356.	0.4	0
362	[ICâ€“Pâ€“036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P32.	0.4	0
363	[ICâ€“Pâ€“053]: EARLY ALTERATIONS IN RESTINGâ€“STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P43.	0.4	0
364	[ICâ€“Pâ€“058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P47.	0.4	0
365	[ICâ€“Pâ€“065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P53.	0.4	0
366	[ICâ€“Pâ€“167]: ACROSSâ€“SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTIâ€“SITE 3T STUDY. Alzheimer's and Dementia, 2017, 13, P126.	0.4	0
367	[P1â€“250]: DECISION TREE ANALYSIS REVEALS TWO CUTâ€“OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P342.	0.4	0
368	[P1â€“289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF AÎ² OR AMYLOIDâ€“PET) IN THE EMIFâ€“AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.4	0
369	[P1â€“387]: CHARACTERIZATION OF SUSPECTED NONâ€“ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING. Alzheimer's and Dementia, 2017, 13, P414.	0.4	0
370	[P1â€“404]: EARLY ALTERATIONS IN RESTINGâ€“STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P429.	0.4	0
371	[P1â€“411]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P433.	0.4	0
372	[P1â€“575]: PREVALENCE OF THE APOLIPOPROTEIN E Î¼4 ALLELE IN AMYLOIDâ€“Î² POSITIVE SUBJECTS ACROSS THE SPECTRUM OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P515.	0.4	0
373	[F1â€“04â€“02]: EPAD REGISTRY. Alzheimer's and Dementia, 2017, 13, P178.	0.4	0
374	[F1â€“04â€“04]: EUROPEAN MEDICAL FRAMEWORK FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P178.	0.4	0
375	[O1â€“05â€“03]: CSF AMYLOID BETA 1â€“42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€“DEPENDENT UPWARD DRIFT. Alzheimer's and Dementia, 2017, 13, P198.	0.4	0
376	[O2â€“05â€“01]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P559.	0.4	0
377	[O3â€“06â€“03]: THE IMPACT OF AMYLOID AND TAU PATHOLOGY ON THE DEVELOPMENT OF SUBTLE COGNITIVE CHANGES IN PERSONS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2017, 13, P912.	0.4	0
378	[P2â€“194]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NONâ€“ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P680.	0.4	0

#	ARTICLE	IF	CITATIONS
379	P3â€216: IS THE RELATION BETWEEN BLOOD PRESSURE AND COGNITION DEPENDENT ON AMYLOID PATHOLOGY OR PHYSICAL PERFORMANCE? RESULTS OF THE EMIFâ€AD 90+ STUDY. Alzheimer's and Dementia, 2018, 14, P1153.	0.4	0
380	P3â€368: PREDICTING AND MONITORING SHORTâ€TERM DISEASE PROGRESSION IN Aâ€MCI PATIENTS WITH PRODROMAL AD USING MRI STRUCTURAL BRAIN BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P1230.	0.4	0
381	P2â€270: INCREASED CSF AMYLOIDâ€ β 1â€38 AND 1â€40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P780.	0.4	0
382	ICâ€Pâ€066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. Alzheimer's and Dementia, 2018, 14, P59.	0.4	0
383	P3â€233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2018, 14, P1161.	0.4	0
384	O1â€13â€01: ROLE OF THE INFLAMMASOME COMPLEX IN ADâ€RELATED HIPPOCAMPAL NEURODEGENERATION IN MCI PATIENTS WITH AD PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P251.	0.4	0
385	P1â€418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. Alzheimer's and Dementia, 2018, 14, P465.	0.4	0
386	P1â€525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2018, 14, P533.	0.4	0
387	F1â€02â€04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P204.	0.4	0
388	P3â€264: UNBIASED METHOD TO DETERMINE CUTâ€POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. Alzheimer's and Dementia, 2018, 14, P1176.	0.4	0
389	O2â€09â€06: FREQUENCIES OF CEREBROSPINAL FLUID A/T/N BIOMARKER PROFILES AND THEIR ASSOCIATION WITH MEMORY FUNCTION IN PERSONS WITHOUT DEMENTIA. Alzheimer's and Dementia, 2018, 14, P643.	0.4	0
390	O2â€09â€05: EXTENSION AND VALIDATION OF AN AMYLOID STAGING MODEL: ASSOCIATIONS WITH CLINICAL MEASURES. Alzheimer's and Dementia, 2018, 14, P643.	0.4	0
391	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.4	0
392	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. Alzheimer's and Dementia, 2018, 14, P1638.	0.4	0
393	ICâ€Pâ€005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸ F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P16.	0.4	0
394	P3â€585: COGNITIVE RESERVE MODULATES THE ASSOCIATION OF CEREBRAL AMYLOID PATHOLOGY WITH COGNITIVE PERFORMANCE IN PERSONS WITH ALZHEIMER'S DISEASE DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1349.	0.4	0
395	P3â€568: PROGNOSIS OF INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT REVERTING TO NORMAL COGNITION. Alzheimer's and Dementia, 2018, 14, P1341.	0.4	0
396	F1â€02â€02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P201.	0.4	0

#	ARTICLE	IF	CITATIONS
397	P3â€³55: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸ F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI-QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P1221.	0.4	0
398	F1â€²02â€²01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENTâ€²LIGHT AND YKLâ€²40 TO AÎ², APOE Îµ4 AND COGNITION: RESULTS FROM THE EMIFâ€²AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P201.	0.4	0
399	P2â€²458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€²AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.4	0
400	F1â€²02â€²03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIFâ€²AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P202.	0.4	0
401	P4â€²077: BLOOD INFLAMMATORY PROFILES MEASURED BY THE ADFLAG^{Â®} TEST ENABLE STRATIFICATION OF PREâ€²DEMEMENTIA ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1464.	0.4	0
402	Personality and Dementia. , 2018, , 83-110.		0
403	P4â€²525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515.	0.4	0
404	ICâ€²Paâ€²015: VOXELâ€²BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM</i>. Alzheimer's and Dementia, 2019, 15, P24.	0.4	0
405	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. Alzheimer's and Dementia, 2020, 16, e037912.	0.4	0
406	CSF proteomic changes in preâ€²preclinical Alzheimerâ€²TM's disease: A monozygotic twin study. Alzheimer's and Dementia, 2020, 16, e038966.	0.4	0
407	The impact of a nutritional intervention in prodromal Alzheimerâ€²TM's disease: The LipiDiDiet clinical trial. Alzheimer's and Dementia, 2020, 16, e039846.	0.4	0
408	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. Alzheimer's and Dementia, 2020, 16, e040152.	0.4	0
409	Amygdalar nuclei and hippocampal subfields on MRI: Testâ€²retest reliability of automated segmentation in old and young healthy volunteers. Alzheimer's and Dementia, 2020, 16, e040322.	0.4	0
410	General practitionersâ€²TM opinion on early and preâ€²dementia diagnosis of AD: A MOPEAD project survey in five European countries. Alzheimer's and Dementia, 2020, 16, e040357.	0.4	0
411	Functional interpretation of genetic risk loci for dementia using a protein quantitative trait loci (pQTLs) approach in cerebrospinal fluid. Alzheimer's and Dementia, 2020, 16, e040774.	0.4	0
412	Amyloidâ€²Î² deposition in cognitively normal oldestâ€²old is associated with cortical thinning and faster memory decline. Alzheimer's and Dementia, 2020, 16, e040991.	0.4	0
413	Research diagnostic criteria for Alzheimerâ€²TM's disease: Findings from the multinational LipiDiDiet Trial. Alzheimer's and Dementia, 2020, 16, e042530.	0.4	0
414	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e042739.	0.4	0

#	ARTICLE	IF	CITATIONS
415	Amyloid β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e042768.	0.4	0
416	Amyloid-dependent association of grey matter network disruptions with phospho τ in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044739.	0.4	0
417	Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins. <i>Alzheimer's and Dementia</i> , 2020, 16, e045112.	0.4	0
418	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e045196.	0.4	0
419	Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e045470.	0.4	0
420	Plasma amyloid β oligomerization assay as a screening test for abnormal amyloid status. <i>Alzheimer's and Dementia</i> , 2020, 16, e045754.	0.4	0
421	DNA methylation differences associated with peripheral biomarkers in the EMIF-AD cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e045853.	0.4	0
422	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. <i>Alzheimer's and Dementia</i> , 2020, 16, e045876.	0.4	0
423	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimer's and Dementia</i> , 2020, 16, e046102.	0.4	0
424	AB0728...MICROVASCULAR CHANGES OF THE RETINA IN ANKYLOSING SPONDYLITIS, AND THE ASSOCIATION WITH CARDIOVASCULAR DISEASE - THE EYE FOR A HEART STUDY.. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1658.2-1659.	0.5	0
425	Decorin is an early CSF biomarker of Alzheimer's β amyloidosis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
426	Associations between CSF proteins and medial temporal lobe atrophy across the AD continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
427	The association between diabetes and Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
428	Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
429	Amyloid discordance analysis in cognitively normal monozygotic twins demonstrates that the memory domain is affected first in preclinical AD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
430	Is A+ τ -Alzheimer's disease or not? A combined CSF and pathology study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
431	Associations of lifestyle factors with amyloid positivity in cognitively normal individuals at different levels of genetic risk: The amyloid biomarker study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
432	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
433	Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [¹⁸ F]flortaucipir PET study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
434	Alzheimer's disease genetic risk variants show brain cell type-specific associations with protein levels in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2021, 17, e049531.	0.4	0
435	Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
436	Plasma τ 181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
437	Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
438	CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
439	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer's disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification. <i>Alzheimer's and Dementia</i> , 2021, 17, e053030.	0.4	0
440	Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e055451.	0.4	0